Management of Hypertension After ARB Allergy

Primary Recommendation: Calcium Channel Blockers

The American College of Cardiology and American Heart Association recommend adding a dihydropyridine calcium channel blocker, specifically amlodipine, as the next-line agent when a patient on a beta blocker has developed an allergy to ARBs, due to their complementary mechanism of action and proven cardiovascular benefits 1, 2, 3
Dihydropyridine CCBs, such as amlodipine and nifedipine, are the preferred add-on therapy to beta blockers when ARBs cannot be used due to allergy, based on ACC/AHA hypertension guidelines 1, 2, 3
The combination of dihydropyridine CCBs and beta blockers provides additive blood pressure reduction without overlapping pathways that could increase adverse effects, and is suitable for both hypertension and coronary artery disease management 1, 2, 3
Dihydropyridine CCBs can be safely combined with beta blockers without excessive bradycardia or heart block, making them a preferred choice over non-dihydropyridine CCBs 1, 3

For patients with heart failure with reduced ejection fraction who cannot tolerate ACE inhibitors or ARBs due to allergy or intolerance, the American College of Cardiology recommends hydralazine plus isosorbide dinitrate as an alternative, with a Class IIb recommendation 4, 5
This combination is particularly beneficial in African American patients with persistent symptoms despite beta blocker therapy, and requires concurrent diuretic therapy and beta blocker use to mitigate sodium retention and reflex tachycardia 4, 5
Thiazide or thiazide-like diuretics, such as chlorthalidone and hydrochlorothiazide, represent another rational add-on option for additional blood pressure control, providing a complementary mechanism through volume reduction and being effective when combined with beta blockers for hypertension management 1, 3, 4

The American College of Cardiology and American Heart Association state that if a patient had angioedema with an ARB, another ARB or ACE inhibitor should never be used, due to the risk of cross-reactivity and life-threatening angioedema 7, 6, 8
Neprilysin inhibitors, such as sacubitril-valsartan, are absolutely contraindicated in any patient with a history of angioedema, and extreme caution is advised when substituting an ARB after ACE inhibitor angioedema 7, 6, 8

When initiating CCB therapy after ARB discontinuation, blood pressure should be monitored, including orthostatic measurements, within 1-2 weeks, and patients should be assessed for peripheral edema and reflex tachycardia 6, 1, 3
Amlodipine should be started at a dose of 5 mg once daily, titrating to 10 mg once daily as needed for blood pressure control, with steady-state levels reached after 7-8 days of consecutive dosing 1, 3